Differential expression of gene profiling in therapeutic response and non-response cervical carcinoma

Simple item page
dc.contributor.authorMontira Sakunjia; Master of Science Program in Medical Sciences, Khon Kaen Universityen_US
dc.contributor.authorPatcharee Jearanaikoon; Centre for Research and Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences, Khon Kaen Universityen_US
dc.contributor.authorPisamai Yuenyao; Department of Obstetrics and Gynaecology, Faculty of Medicine, Khon Kaen Universityen_US
dc.contributor.authorInthira Tussakhonen_US
dc.contributor.authorTemduang Limpaiboon; Centre for Research and Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences, Khon Kaen Universityen_US
dc.date.accessioned2011-02-20T04:32:57Z
dc.date.available2011-02-20T04:32:57Z
dc.date.created2010-04-11en_US
dc.date.issued2010-04-11en_US
dc.description.abstractCervical carcinoma is one of the most common malignancies in women worldwide. Persistent infection with high risk human papillomavirus is the most significant factor for carcinogenesis of cervical cancer. Therapeutic modalities of cervical carcinoma are not efficiently controlling the progression of cancer in one third of patients. Therefore, understanding of molecular mechanisms in cancer progression is important to prevent disease progression and improve treatment efficacy leading to the reduction of incidence and mortality rate. We investigated genes differentially expressed in therapeutic response and non–response cervical carcinoma stage IIIB using the human whole genome microarrays. The differential expression of genes in each group was constructed for the network by IPA software. Differentially expressed genes in non–responses compared with responses were identified, which were 167 up-regulated and 146 down-regulated genes. The up-regulated genes have biological functions involved in signal transduction (CXCL10, ERBB2, TRAF5, FPRL1, IL1B, FGFBP1 and SCTR), cell proliferation (REG1A, AREG, TGFBI, ERBB2, PIM2, EIF5A and ISG20), proteolysis (PLAU, CRADD, C1R, KLK14, TMEM27, ICEBERG, BF and ADAMTS8), and cell migration (ERBB2, IL8, IL1B, and FPRL1). The down-regulated genes have biological functions involved in transcription (GLIS1, ZNF337, SOX4, PITX1, LASS4, GRHL3, CRABP2, SUHW3, TLE2 and KLF8), cell adhesion (PCDHB6, TRO, MAGI1, PVRL4, SLURP1 and MUC4), and signal transduction (CD38, CXCL14, HTR2B, CEACAM6, DPYSL3, NCR1, CRABP2, CLIC3, TLE2 and PLXNA2). Our study indicates that multiple genes play distinct roles in response or non-response to therapy in cervical carcinoma.en_US
dc.identifier.citationJournal of Medical Technology and Physical Therapy; Volume 22 Number 1, January - April 2010; 5-16en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/130893
dc.language.isoen_USen_US
dc.publisherKhon Kaen Universityen_US
dc.rightsKhon Kaen Universityen_US
dc.source.urihttps://thailand.digitaljournals.org/index.php/JMTPT/issue/archiveen_US
dc.source.urihttps://thailand.digitaljournals.org/index.php/JMTPT/article/view/3375en_US
dc.titleDifferential expression of gene profiling in therapeutic response and non-response cervical carcinomaen_US
dc.typeORIGINAL ARTICLEen_US
Files
Collections
Journal of Medical Technology and Physical Therapy